Proprietary Gen 2 technology
Leveraging the initial success of the NCI processes, we set out to develop centralized, scalable and proprietary processes to manufacture Iovance TIL therapies. Our proprietary Gen 2 technology includes manufacturing and logistical efficiencies aimed at further optimizing treatment, decreasing production time and streamlining distribution processes. Today, more than 500 patients have been treated with investigational TIL therapy from Iovance, with a manufacturing success rate above 90%.
Streamlined 22-day GMP manufacturing process
Our 16-day, Gen 3 process
In some of our clinical trials, we are also exploring a Gen 3 process which reduces manufacturing to 16 days. The third generation of our process is expected to reduce the wait time between initial tumor sample and infusion for patients.
GMP=good manufacturing practice; IL-2=interleukin-2; NMA-LD=nonmyeloablative lymphodepletion
TIL therapy is an investigational therapy and has not been approved for any indication by the Food and Drug Administration (FDA) or any other regulatory agency. The safety and efficacy of this therapy have not been determined.